The Conversation (0)
InMed Pharmaceuticals signed an agreement with Pharmaseed to develop a final formulation for InMed’s lead compound, INM-750.
InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) signed an agreement with Pharmaseed to develop a final formulation for InMed’s lead compound, INM-750.
As quoted in the press release:
INM-750, a proprietary, topical cannabinoid product candidate intended as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications.
“This agreement with Pharmaseed now adds one of Israel’s leading formulation development teams to our efforts and represents an important strategic relationship as we move INM-750 towards our first clinical trial,” stated Eric A. Adams, CEO of InMed.
Under the agreement, Pharmaseed will develop a final formulation for INM-750 for continued R&D including IND-enabling pharmacology and toxicology studies and subsequent clinical studies. Also included under the scope of the contract is the development of assay methods for manufacturing, stability, quality assurance and other analytical methods.
Click here to read the full press release.
Source: www.newswire.ca
